Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Actinium Pharmaceuticals (ATNM) Non Operating Income (2021 - 2025)

Actinium Pharmaceuticals (ATNM) has disclosed Non Operating Income for 8 consecutive years, with -$665000.0 as the latest value for Q4 2025.

  • Quarterly Non Operating Income changed N/A to -$665000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.2 million through Dec 2025, changed N/A year-over-year, with the annual reading at $2.4 million for FY2025, 39.14% down from the prior year.
  • Non Operating Income for Q4 2025 was -$665000.0 at Actinium Pharmaceuticals, down from $561000.0 in the prior quarter.
  • The five-year high for Non Operating Income was $1.1 million in Q3 2023, with the low at -$665000.0 in Q4 2025.
  • Average Non Operating Income over 5 years is $453947.4, with a median of $547000.0 recorded in 2023.
  • The sharpest move saw Non Operating Income soared 1594.74% in 2022, then crashed 45.69% in 2025.
  • Over 5 years, Non Operating Income stood at $38000.0 in 2021, then surged by 1594.74% to $644000.0 in 2022, then surged by 58.23% to $1.0 million in 2023, then increased by 1.37% to $1.0 million in 2024, then plummeted by 164.38% to -$665000.0 in 2025.
  • According to Business Quant data, Non Operating Income over the past three periods came in at -$665000.0, $561000.0, and $625000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.